Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 25Neoplasms 8Neoplasm Metastasis 8Colorectal Neoplasms 5Lymphoma, Non-Hodgkin 4Leukemia, Hairy Cell 4Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Skin Neoplasms 1Sarcoma, Clear Cell 1Relapsed Pediatric Solid Tumor 1Rare Tumour 1

Interventions

vandetanib 1ruxolitinib 1pazopanib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Ifosfamide 1Everolimus 1Etoposide 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Carboplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Relapsed Pediatric Solid Tumor × Vemurafenib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡